Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released Jul 30, 2025, before the open
10-Q filed Jul 30, 2025, 30 days after period end · 0001171843-25-004826
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $28.22M | $30.72M | $44.30M | $39.66M |
| Net Income | -$3.97M | -$88.00K | -$2.74M | -$2.84M |
| EPS Diluted |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.28 |
| $0.00 |
| -$0.19 |
| -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
